NEC

193 drugs in development·89 companies·1 clinical trial

Drug Pipeline by Phase

Approved(23)

Drug	Company
abrilada	PFIZER INC (PFE)
adcirca	ELI LILLY & Co (LLY)
adept adhesion reduction	Baxter International Inc. (BAX)
ambrisentan	Mylan II B.V. (MYL)
amjevita	AMGEN INC (AMGN)
avsola	AMGEN INC (AMGN)
Chenodal	Mirum Pharmaceuticals, Inc. (MIRM)
corometrics model 120 f-series maternal/fetal monitor with intergrated fetal oxygen saturation monitoring	GE HealthCare Technologies Inc. (GEHC)
corometrics model 146 fetal acoustic stimulator	GE HealthCare Technologies Inc. (GEHC)
Duphaston™	ABBOTT LABORATORIES (ABT)
epoprostenol	Mylan II B.V. (MYL)
Erbitux	ELI LILLY & Co (LLY)
Erbitux®	ELI LILLY & Co (LLY)
fosinopril	Teva Pharmaceutical Industries Limited (TEVA)
hydroxyurea	AVEDRO INC (AVDR)
MYOBLOC	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Olumiant	ELI LILLY & Co (LLY)
promacta	Novartis AG (NVS)
promacta kit	Novartis AG (NVS)
reality vaginal pouch	Co-Diagnostics Inc. (CODX)
renuvion apr	Apyx Medical Corporation (APYX)
ssi mantra	SS Innovations International Inc. (SSII)
treprostinil	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(31)

Drug	Company
5-flurouracil	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
amivantamab sc	GH Research PLC (GHRS)
AXAL (axalimogene filolisbac / ADXS-HPV)	Ayala Pharmaceuticals, Inc. (ADXS)
AZD5069	ASTRAZENECA PLC (AZN)
AZD9150	ASTRAZENECA PLC (AZN)
Camrelizumab and Cetuximab	FATE THERAPEUTICS INC (FATE)
Camrelizumab and Chemotherapy	FATE THERAPEUTICS INC (FATE)
cetuximab	AVEO PHARMACEUTICALS, INC. (AVEO)
cetuximab	ASTRAZENECA PLC (AZN)
Cetuximab	FATE THERAPEUTICS INC (FATE)
domvanalimab	GILEAD SCIENCES, INC. (GILD)
Erbitux®	Amneal Pharmaceuticals, Inc. (AMRX)
Erbitux®	FATE THERAPEUTICS INC (FATE)
ficerafusp alfa (formerly BCA101)	Bicara Therapeutics Inc. (BCAX)
ficlatuzumab	AVEO PHARMACEUTICALS, INC. (AVEO)
Investigator's Choice	Merus N.V. (MRUS)
MEDI4736	ASTRAZENECA PLC (AZN)
Multikine	CEL SCI CORP (CVM)
nbtxr3	LianBio (LIANY)
pds0101	PDS Biotechnology Corp (PDSB)
petosemtamab	Merus N.V. (MRUS)
Remzistotug	iTeos Therapeutics, Inc. (ITOS)
rp1 in combination with nivolumab	Replimune Group, Inc. (REPL)
RPH-002	Amneal Pharmaceuticals, Inc. (AMRX)
RPH-002	FATE THERAPEUTICS INC (FATE)
tak-186	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Tarlatamab	REGENXBIO Inc. (RGNX)
Tarlatamab	Merus N.V. (MRUS)
Xevinapant	Merck & Co., Inc. (MRK)
zimberelimab	GILEAD SCIENCES, INC. (GILD)

Phase 2(35)

Drug	Company
Amivantamab	Structure Therapeutics Inc. (GPCR)
Amivantamab and Recombinant Human Hyaluronidase	Structure Therapeutics Inc. (GPCR)
Amivantamab IV	Structure Therapeutics Inc. (GPCR)
Amivantamab SC	Structure Therapeutics Inc. (GPCR)
BT8009	BICYCLE THERAPEUTICS PLC (BCYC)
cemiplimab	West Pharmaceutical Services Inc. (WST)
Cemiplimab	ELI LILLY & Co (LLY)
cmp-001	CHECKMATE PHARMACEUTICALS, INC. (CMPI)
cylembio	IO Biotech, Inc. (IOBT)
Dostarlimab	Merus N.V. (MRUS)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
eseba-vec	HOOKIPA Pharma Inc. (HOOK)
fdc fianlimab+cemiplimab	West Pharmaceutical Services Inc. (WST)
FID-007	Fulgent Genetics Inc. (FLGT)
FID007	Fulgent Genetics Inc. (FLGT)
fs118	F-star Therapeutics, Inc. (FSTX)
gedeptin	GeoVax Labs, Inc. (GOVX)
GSK5764227	Merus N.V. (MRUS)
hb-200	HOOKIPA Pharma Inc. (HOOK)
IMGN151	AbbVie Inc. (ABBV)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)
rtx-224	Rubius Therapeutics, Inc. (RUBY)
Sacituzumab Govitecan	FATE THERAPEUTICS INC (FATE)
sar444245	Sanofi (SNY)
Setanaxib	Calliditas Therapeutics AB (CALT)
sgx942	SCICLONE PHARMACEUTICALS INC (SCLN)
si-b001	NYMOX PHARMACEUTICAL CORP (NYMXF)
skb518	GH Research PLC (GHRS)
versamune hpv	PDS Biotechnology Corp (PDSB)
vidutolimod	CHECKMATE PHARMACEUTICALS, INC. (CMPI)
vobramitamab duocarmazine	MACROGENICS INC (MGNX)
Vobramitamab Duocarmazine (vobra duo)	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.0 mg	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.7 mg	MACROGENICS INC (MGNX)
zelenectide pevedotin (formerly BT8009)	BICYCLE THERAPEUTICS PLC (BCYC)

Phase 1(57)

Drug	Company
aldesleukin	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
amivantamab	GH Research PLC (GHRS)
BI 770371	FATE THERAPEUTICS INC (FATE)
BI 770371	Amneal Pharmaceuticals, Inc. (AMRX)
Birinapant	IGM Biosciences, Inc. (IGMS)
cetuximab	Incyte Corp. (INCY)
Cetuximab	NEKTAR THERAPEUTICS (NKTR)
CIML NK cell Infusion	Amneal Pharmaceuticals, Inc. (AMRX)
CIML NK cell Infusion	FATE THERAPEUTICS INC (FATE)
CLD-201 (SuperNova™ / SNV1)	Calidi Biotherapeutics Inc. (CLDI)
CUE-101	Cue Biopharma, Inc. (CUE)
fpi-1966	Fusion Pharmaceuticals Inc. (FUSN)
gen-011	GENOCEA BIOSCIENCES, INC. (GNCA)
Interleukin-15 Superagonist	FATE THERAPEUTICS INC (FATE)
Interleukin-15 Superagonist	Amneal Pharmaceuticals, Inc. (AMRX)
jnj-90301900	Innovation Pharmaceuticals Inc. (IPIX)
jnj-90301900	JOHNSON & JOHNSON (JNJ)
NKTR-0165	NEKTAR THERAPEUTICS (NKTR)
NKTR-255	NEKTAR THERAPEUTICS (NKTR)
NKTR-288	NEKTAR THERAPEUTICS (NKTR)
NKTR-422	NEKTAR THERAPEUTICS (NKTR)
Polymer-conjugated IL-15 Receptor Agonist NKTR-255	NEKTAR THERAPEUTICS (NKTR)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)
RP3	Replimune Group, Inc. (REPL)
sl-279252	Shattuck Labs, Inc. (STTK)
STRO-004	SUTRO BIOPHARMA, INC. (STRO)
tagmokitug	Coherus Oncology, Inc. (CHRS)
tbio-4101	GH Research PLC (GHRS)
tsc-200-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-200-a0201 + tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-200-a0201 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-200-a0201 + tsc-203-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-200-a0201 + tsc-204-a0101	TScan Therapeutics, Inc. (TCRX)
tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-201-b0702 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-203-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-203-a0201 + tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-203-a0201 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-203-a0201 + tsc-204-a0101	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0101	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0101 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-200-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-203-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-204-a0101	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201 + tsc-204-c0702	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702 + tsc-200-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702 + tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702 + tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702 + tsc-203-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702 + tsc-204-a0101	TScan Therapeutics, Inc. (TCRX)
uza-cel	Adaptimmune Therapeutics PLC (ADAP)

Preclinical(8)

Drug	Company
apvo455	Aptevo Therapeutics Inc. (APVO)
gtb-5550	GT Biopharma, Inc. (GTBP)
io112	IO Biotech, Inc. (IOBT)
ipoxyn	NANOMIX CORP (BTHI)
lnth-2403	Lantheus Holdings, Inc. (LNTH)
nktr-0166	NEKTAR THERAPEUTICS (NKTR)
theralink pan-tumor assay 1.0	THERALINK TECHNOLOGIES, INC. (THER)
VPS4A inhibitors (novel series)	Calithera Biosciences, Inc. (CALA)

Unknown(6)

Drug	Company
AR101	AYTU BIOPHARMA, INC (AYTU)
Equine All-in-One™	BIOADAPTIVES, INC. (BDPT)
Equine Regen®	BIOADAPTIVES, INC. (BDPT)
femidom	HEALTH-RIGHT DISCOVERIES, INC. (HRDV)
intergel adhesion prevention	LIFECORE BIOMEDICAL, INC. DE (LFCR)
Vital-Q - Flawless Neck - CBD Formula with Hemp Extracts	Bioquest Corp (BQST)

Phase 1/Phase 2(8)

Drug	Company
aldesleukin	Alaunos Therapeutics, Inc. (TCRT)
allogeneic umbilical cord mesenchymal stem cells	Curative Biotechnology Inc (CUBT)
cetuximab	Sanofi (SNY)
GTAEXS617	RECURSION PHARMACEUTICALS, INC. (RXRX)
micvotabart pelidotin	Pyxis Oncology, Inc. (PYXS)
neoantigen specific tcr-t cell drug product	Alaunos Therapeutics, Inc. (TCRT)
tak-186	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tqb2922	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2/Phase 3(3)

Drug	Company
BNT113	BioNTech SE (BNTX)
ficerafusp alfa	Bicara Therapeutics Inc. (BCAX)
inbrx-106	Inhibrx Biosciences, Inc. (INBX)

Phase 4(22)

Drug	Company
5-Flurouracil	Merus N.V. (MRUS)
5-FU	KYNTRA BIO INC. (KYNB)
Lidocaine Infusion	Structure Therapeutics Inc. (GPCR)
Lidocaine Infusion	Filana Therapeutics Inc. (FLNA)
Lidocaine Infusion	PROTHENA CORP PUBLIC LTD CO (PRTA)
Monalizumab	ASTRAZENECA PLC (AZN)
Multimodal IV analgesia	Structure Therapeutics Inc. (GPCR)
Multimodal IV analgesia	PROTHENA CORP PUBLIC LTD CO (PRTA)
Multimodal IV analgesia	Filana Therapeutics Inc. (FLNA)
Multimodal IV analgesia	Cidara Therapeutics, Inc. (CDTX)
Multimodal IV analgesia	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Multimodal IV analgesia	Crinetics Pharmaceuticals, Inc. (CRNX)
Nefopam 120mg/day infusion	Filana Therapeutics Inc. (FLNA)
Nefopam 120mg/day infusion	PROTHENA CORP PUBLIC LTD CO (PRTA)
Nefopam 120mg/day infusion	Structure Therapeutics Inc. (GPCR)
Peridural	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Peridural	Filana Therapeutics Inc. (FLNA)
Peridural	PROTHENA CORP PUBLIC LTD CO (PRTA)
Peridural	Cidara Therapeutics, Inc. (CDTX)
Peridural	Structure Therapeutics Inc. (GPCR)
Peridural	Crinetics Pharmaceuticals, Inc. (CRNX)
prabotulinumtoxinA-xvfs	Revance Therapeutics, Inc. (RVNC)

Compare drugs

abrilada vs adcirca abrilada vs adept adhesion reduction abrilada vs ambrisentan

Frequently asked questions

How many drugs are in development for NEC?

BioSniper tracks 193 drugs in development for NEC across 89 companies.

How many clinical trials target NEC?

There are 1 clinical trial targeting NEC tracked by BioSniper.

Deep-dive into NEC

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis